Item 8.01 Other Events.
On October 14, 2020, the Company issued two press releases announcing the
topline data from the Company's IW-6463 Translational Pharmacology Study and its
olinciguat Phase 2 STRONG-SCD study in patients with SCD. Copies of the press
releases regarding IW-6463 and olinciguat are attached hereto as Exhibit 99.1
and Exhibit 99.2, respectively, and each is incorporated by reference to this
Current Report on Form 8-K.
The Company will host a conference call to discuss the topline results from the
IW-6463 translational pharmacology study on October 14, 2020 at 8:30
a.m. Eastern Time. A copy of the conference call presentation materials is
attached hereto as Exhibit 99.3 and is incorporated by reference to this Current
Report on Form 8-K. The presentation materials are also available on the
"Investors & Media" page of the Company's website at
https://ir.cyclerion.com/news-events/news-releases.
All information included in the press releases and the investor presentation is
presented as of the respective dates thereof, and the Company assumes no
obligation to correct or update such information in the future.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit No. Description
99.1 Press Release of Cyclerion Therapeutics, Inc. dated October 14,
2020
99.2 Press Release of Cyclerion Therapeutics, Inc. dated October 14,
2020
99.3 Investor Presentation of Cyclerion Therapeutics, Inc. dated
October 14, 2020
2
© Edgar Online, source Glimpses